2023
DOI: 10.1002/ehf2.14278
|View full text |Cite
|
Sign up to set email alerts
|

Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO‐D registry

Abstract: Aim Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term. In this real‐life registry, we describe the patterns of use, safety and factors related to the response to intermittent levosimendan infusions in AHF patients not candidates to advanced therapies. Methods and results Multicentre retrospective study o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 21 publications
0
10
0
1
Order By: Relevance
“…Regarding clinical and treatment variables included in the calculators, in the LEVO‐D registry, age was not related to 1‐year outcomes, reflecting the short survival expectancy of this population and neither did neurohormonal blockade use 6 . AHF patients are clearly underrepresented in pivotal HF trials, but subgroup analysis suggests that treatment effects on hard endpoints are at least attenuated 17,18 .…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…Regarding clinical and treatment variables included in the calculators, in the LEVO‐D registry, age was not related to 1‐year outcomes, reflecting the short survival expectancy of this population and neither did neurohormonal blockade use 6 . AHF patients are clearly underrepresented in pivotal HF trials, but subgroup analysis suggests that treatment effects on hard endpoints are at least attenuated 17,18 .…”
Section: Discussionmentioning
confidence: 99%
“…16 Regarding clinical and treatment variables included in the calculators, in the LEVO-D registry, age was not related to 1-year outcomes, reflecting the short survival expectancy of this population and neither did neurohormonal blockade use. 6 AHF patients are clearly underrepresented in pivotal HF trials, but subgroup analysis suggests that treatment effects on hard endpoints are at least attenuated. 17,18 On the contrary, other markers of AHF, such as prior inotropic use, impaired haemodynamic profile, HF drug down titration, worsening right ventricular function and ventricular arrhythmias/ ICD shocks are currently not included in any of the studied calculators.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations